From: Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer
Variable
Patients, N (%)
CR
1 (2.7)
PR
26 (70.3)
SD
3 (8.1)
PD
7 (18.9)
ORR
27 (73.0)
DCR
30 (81.1)
Surgical conversion
22 (59.5)
R0 resection
14 (63.6)